Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene + Azacitidine +/- Venetoclax in CMML
NCT06085638Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label trial of tamibarotene in chronic myelomonocytic leukemia (CMML) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events. Planned start Sep 2023; status: withdrawn.
02
Drugs
tamibarotene
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06085638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085638.